ASX Share rice
Mon 17 May 2021 - 05:13:am (Sydney)

BNO Share Price

BIONOMICS LIMITEDBNOPharmaceuticals, Biotechnology & Life Sciences

BNO Company Information

Name:

Bionomics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

31 Dalgleish Street Thebarton SA Australia 5031

Phone:

61 8 8354 6100

Exec. Chairman:

Dr. Errol B. De Souza

Acting Chief Financial Officer:

Mr. Adrian Hinton

Consultant Chief Medical Officer of Clinical Neuroscience:

Prof. Paul Rolan

Company Sec.:

Ms. Suzanne Irwin B.Com., FCIS

Company Overview:

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

BNO Share Price Information

Shares Issued:

1B

Market Capitalisation:

$210.77M

Revenue (TTM):

$2.19M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.02

Profit Margin:

-0.1966

Operating Margin (TTM):

$-3.43

Return On Assets (TTM):

$-0.13

Return On Equity (TTM):

$0.05

Quarterly Revenue Growth (YOY):

-0.586

Gross Profit(TTM):

$-2,635,298

Diluted Earnings Per Share (TTM):

$-0.001

BNO CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$497.83K

Change To Liabilities:

$-121,129

Total Cashflow From Investing Activities:

$-195,131

Net Borrowings:

$-8,287,122

Net Income:

$-7,118,288

Total Cash From Operating Activities:

$-3,903,193

Depreciation:

$2.17M

Other Cashflow From Investing Activities:

$-949,623

Change To Inventory:

$-28,291

Change To Account Receivables:

$-202,257

Sale Purchase Of Stock:

$3.26M

Capital Expenditures:

$7.70K

BNO Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-6,026,590

Net Income:

$-7,118,290

Gross Profit:

$46.66K

Operating Income:

$-4,412,420

Interest Expense:

$1.77M

Income Tax Expense:

$-207,612

Total Revenue:

$246.95K

BNO Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$11.77M

Total Liabilities:

$21.78M

Total Stockholder Equity:

$12.68M

Total Assets:

$34.46M

Common Stock:

$148.16M

Other Current Assets:

$2.92M

Retained Earnings:

$-148,887,782

Other Liabilities:

$7.22M

Good Will:

$12.87M

Other Assets:

$436.17K

Cash:

$4.58M

Total Current Liabilities:

$8.27M

Property - Plant & Equipment:

$1.05M

Net Tangible Assets:

$-11,956,792

Long-Term Investments:

$436.17K

Total Current Assets:

$8.33M

Long-Term Debt:

$6.26M

Net Receivables:

$2.98M

Short-Term Investments:

$26.13M

Accounts Payable:

$1.26M

Short-Term Investments:

$26.13

Non Current Liabilities (Other):

$4.98M

Non Current Liabilities Total:

$13.51M

BNO Share Price History

BNO News

10 May, 2021
Bionomics Limited (OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder (PTSD) in the middle of this year.
13 Apr, 2021
Investment supports phase IIb clinical trial examining novel PTSD treatmentTORONTO, ON / ACCESSWIRE / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has increased its strategic investment in Bionomics Limited ("Bionomics") (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
09 Apr, 2021
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurrent placement that was announced on 17 March 2021 (Concurrent Placement) which collectively raised approximately A$22.9 million.
15 Mar, 2021
Bionomics Limited ( ASX:BNO ) shareholders might be concerned after seeing the share price drop 15% in the last week...
22 Feb, 2021
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, today announced positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210. BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).
17 Feb, 2021
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
11 Feb, 2021
Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD TreatmentTORONTO, ON / ACCESSWIRE / February 11, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the "Strategic Investment"), in Bionomics Limited ("Bionomics") (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
10 Feb, 2021
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, is pleased to announce that it has entered into placement agreements with a number of North American and European institutional and sophisticated investors, to raise A$15,991,634. The Company used its 15% placement capacity under Listing Rule 7.1 of 110,287,132 shares.
16 Sep, 2020
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
02 Jun, 2020
Bionomics A$20-A$22 million recapitalisation led by Apeiron Investment Group